Clinical Trial Update: Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating long-acting octreotide for idiopathic pulmonary fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Sandostatin LAR (octreotide)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1, Phase 2 | Status: COMPLETED